bluebird bio Statistics
Total Valuation
bluebird bio has a market cap or net worth of $40.04 million. The enterprise value is $349.44 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
bluebird bio has 9.79 million shares outstanding. The number of shares has increased by 76.45% in one year.
| Current Share Class | 9.79M |
| Shares Outstanding | 9.79M |
| Shares Change (YoY) | +76.45% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 28.04% |
| Float | 9.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.50 |
| Forward PS | 0.14 |
| PB Ratio | -1.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48
| Current Ratio | 0.48 |
| Quick Ratio | 0.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.86 |
Financial Efficiency
Return on equity (ROE) is -295.35% and return on invested capital (ROIC) is -38.62%.
| Return on Equity (ROE) | -295.35% |
| Return on Assets (ROA) | -31.00% |
| Return on Invested Capital (ROIC) | -38.62% |
| Return on Capital Employed (ROCE) | -192.91% |
| Revenue Per Employee | $337,931 |
| Profits Per Employee | -$970,625 |
| Employee Count | 248 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, bluebird bio has paid $70,000 in taxes.
| Income Tax | 70,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.55% in the last 52 weeks. The beta is 0.47, so bluebird bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -78.55% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 9.92 |
| Relative Strength Index (RSI) | 43.15 |
| Average Volume (20 Days) | 527,412 |
Short Selling Information
The latest short interest is 1.78 million, so 18.15% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short Previous Month | 1.85M |
| Short % of Shares Out | 18.15% |
| Short % of Float | 18.28% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
In the last 12 months, bluebird bio had revenue of $83.81 million and -$240.72 million in losses. Loss per share was -$24.84.
| Revenue | 83.81M |
| Gross Profit | -5.57M |
| Operating Income | -267.70M |
| Pretax Income | -91.14M |
| Net Income | -240.72M |
| EBITDA | -206.46M |
| EBIT | -267.70M |
| Loss Per Share | -$24.84 |
Full Income StatementBalance Sheet
The company has $62.31 million in cash and $370.53 million in debt, giving a net cash position of -$308.22 million or -$31.48 per share.
| Cash & Cash Equivalents | 62.31M |
| Total Debt | 370.53M |
| Net Cash | -308.22M |
| Net Cash Per Share | -$31.48 |
| Equity (Book Value) | -31.53M |
| Book Value Per Share | -3.24 |
| Working Capital | -166.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$260.02 million and capital expenditures -$2.60 million, giving a free cash flow of -$262.62 million.
| Operating Cash Flow | -260.02M |
| Capital Expenditures | -2.60M |
| Free Cash Flow | -262.62M |
| FCF Per Share | -$26.83 |
Full Cash Flow StatementMargins
Gross margin is -6.65%, with operating and profit margins of -319.42% and -287.23%.
| Gross Margin | -6.65% |
| Operating Margin | -319.42% |
| Pretax Margin | -287.14% |
| Profit Margin | -287.23% |
| EBITDA Margin | -246.35% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
bluebird bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -76.45% |
| Shareholder Yield | -76.45% |
| Earnings Yield | -584.03% |
| FCF Yield | -637.17% |
Dividend DetailsAnalyst Forecast
The average price target for bluebird bio is $44.60, which is 990.47% higher than the current price. The consensus rating is "Hold".
| Price Target | $44.60 |
| Price Target Difference | 990.47% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 48.63% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
bluebird bio has an Altman Z-Score of -15.66 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.66 |
| Piotroski F-Score | 2 |